Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Knight TherapeuticsTSX:GUD +0.10%73 PEG Ratio is 21.92 as of Jul. 24, 2026, which is 45% above its 10-year median of 15.11. GuruFocus rates TSX:GUD with a GF Score™ of 73/100 and a GF Value™ of C$8.65 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 350 Drug Manufacturers companies, Knight Therapeutics ranks worse than 95.43% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Knight Therapeutics's PEG Ratio or its related term are showing as below:
TSX:GUD'
s PEG Ratio Range Over the Past 10 Years
Min: 6.88 Med: 15.11 Max: 23.08
Current: 21.92
During the past 13 years, Knight Therapeutics's highest PEG Ratio was 23.08. The lowest was 6.88. And the median was 15.11.
TSX:GUD's PEG Ratio is ranked worse than 95.43% of 350
companies
in the Drug Manufacturers industry
Industry Median: 1.715
vs TSX:GUD: 21.92
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Knight Therapeutics (TSX:GUD) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Knight Therapeutics PEG Ratio Related Terms
Knight Therapeutics PEG Ratio Historical Data
* Premium members only.
The historical data trend for Knight Therapeutics's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Knight Therapeutics PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Knight Therapeutics's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Knight Therapeutics (TSX:GUD) has a PEG Ratio of 21.92 as of Jul. 24, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Knight Therapeutics and its competitors. This is 45% above median its historical median of 15.11. Over the past decade, Knight Therapeutics' PEG Ratio has ranged from 6.88 to 23.08. According to the industry distribution chart, Knight Therapeutics ranks #334 out of 350 companies in the Drug Manufacturers industry, placing it in the top 95.4%.
Is Knight Therapeutics' PEG Ratio too high?
Knight Therapeutics' current PEG Ratio of 21.92 is 45% above median its 10-year median of 15.11. Over the past 10 years, this metric has ranged from a low of 6.88 to a high of 23.08. The Drug Manufacturers industry median PEG Ratio is 1.72. Knight Therapeutics' value of 21.92 is 1178.1% above this industry median. Based on the distribution chart, Knight Therapeutics ranks #334 out of 350 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Knight Therapeutics has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Knight Therapeutics' PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Knight Therapeutics ranks #334 out of 350 companies for PEG Ratio. This places Knight Therapeutics in the lower half of its industry. The industry median PEG Ratio is 1.72. Knight Therapeutics' value of 21.92 is 1178.1% above this benchmark. Historically, Knight Therapeutics' own PEG Ratio has ranged from 6.88 to 23.08 over the past decade. While the company's 10-year median is 15.11 vs. the industry median of 1.72, Knight Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.72, based on 350 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Knight Therapeutics's current PEG Ratio of 21.92 is 1178.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Knight Therapeutics and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Knight Therapeutics's current PEG Ratio is 21.92, which is 45% above median its own 10-year median of 15.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Knight Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Knight Therapeutics (TSX:GUD) is currently considered Modestly Overvalued. The stock's GF Value™ is C$8.65, compared to a current price of C$9.69 — trading 12% above its estimated fair value. The current PEG Ratio is 21.92, which is 45% above median its 10-year median of 15.11 and 1178.1% above the Drug Manufacturers industry median of 1.72. Knight Therapeutics' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Knight Therapeutics (TSX:GUD), the current PEG Ratio is 21.92 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Knight Therapeutics (TSX:GUD) Overvalued in 2026?
Based on GuruFocus' analysis, Knight Therapeutics stock appears to be overvalued.
The current stock price of C$9.69 is trading 12% above its estimated GF Value™ of C$8.65.
GuruFocus considers Knight Therapeutics to be Modestly Overvalued.
Key valuation signals for TSX:GUD:
PEG Ratio: 21.92 (45% above median its 10-year median of 15.11)
GF Value™: C$8.65 vs. price of C$9.69 (12% above fair value)
Industry Position: 1178.1% above the Drug Manufacturers median (#334 of 350)
No single metric tells the full story. See the TSX:GUD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceuticalproducts. and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets. The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically, the company generates revenue from Brazil, Canada, Colombia, Argentina, Mexico, Rest of LATAM, and Others, with the majority revenue generated from the Brazil region.
73GF Score
Get the complete analysis for TSX:GUD
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:GUD has been successfully added to your 
